BMC Cancer最新文献

{"title":"Comorbidity burden in elderly high-grade glioma patients: impact on radiotherapy outcomes.","authors":"Sophia M Leiss, Benedikt Wiestler, Helen X Hou, Daniel Schmottermeyer, Valeriya Sackerer, Christian Diehl, Jan Peeken, Kai Borm, Chiara Negwer, Arthur Wagner, Igor Yakushev, Claire Delbridge, Meike Mitsdörffer, Friederike Schmidt-Graf, Bernhard Meyer, Stephanie Combs, Denise Bernhardt","doi":"10.1186/s12885-025-14957-5","DOIUrl":"10.1186/s12885-025-14957-5","url":null,"abstract":"<p><strong>Background: </strong>Elderly high-grade glioma (HGG) or glioblastoma (GBM) patients face challenging treatment conditions due to comorbidities and age-related factors. The age-adjusted Charlson Comorbidity Index (ACCI) accounts for age and comorbidities and serves as a tool for predicting survival rates in various clinical scenarios. This study examined its prognostic value in elderly HGG patients undergoing radiotherapy (RT) and concurrent chemoradiotherapy (CRT).</p><p><strong>Methods: </strong>We retrospectively analyzed 163 elderly HGG patients (≥ 60 years) treated with radiotherapy (RT) or chemo-RT (CRT) at TUM University Hospital (2001-2021). Kaplan-Meier analysis estimated median overall survival (OS) by ACCI group (≤ 5 vs. ≥6). Multivariate Cox regressions assessed OS and progression-free-survival (PFS) based on fractionation and treatment strategies. Further Cox models evaluated ACCI scores, age, comorbidities, and mortality. A random survival forest (RSF) identified key survival predictors, using permutation importance with bootstrapped confidence intervals.</p><p><strong>Results: </strong>Among the 163 HGG patients, those with greater comorbidities (ACCI ≥ 6) had a shorter median OS (14.8 months) than did those with ACCI ≤ 5 (22.6 months) (log-rank p = 0.463). In the ACCI ≤ 5 subgroup, hypofractionated RT (hRT) alone was significantly associated with worse OS than Stupp was (HR = 85.7, 95% CI: 7.1-914.3, p = 0.0004), whereas no significant differences were detected in the ACCI ≥ 6 subgroup. Hypofractionated RT was associated with improved PFS in patients with an ACCI ≥ 6 (HR = 0.47, 95% CI: 0.24-0.92, p = 0.027), and MGMT methylation better predicted OS (HR = 0.31, p = 0.0039) and PFS (HR = 0.32, p = 0.0059). Diabetes without complications independently predicted worse OS (HR = 2.91 (95% CI: 1.63-5.18, p < 0.001)) and PFS (HR = 2.59 (95% CI: 1.43-4.70, p = 0.002), with a significant interaction between diabetes and the ACCI (HR = 0.26, 95% CI: 0.07-0.91, p = 0.03). RSF models identified age as the key predictor of OS and MGMT methylation as the main predictor of PFS, while ACCI ≥ 6 contributed only modestly (mean drop for OS: 0.025; and PFS: 0.019).</p><p><strong>Conclusions: </strong>The ACCI showed limited and inconsistent prognostic value in elderly glioblastoma patients, while diabetes emerged as the only consistent comorbidity predictor of OS and PFS. These findings suggest that comorbidity burden may influence outcomes but underscore the need for larger studies to clarify the role of the ACCI in treatment stratification.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1496"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of endocervical curettage in detecting CIN2 + in postmenopausal women with persistent high-risk HPV and type 3 transformation zone.","authors":"Maria Teresa Bruno, Antonino Giovanni Cavallaro, Maria Chiara Sudano, Maria Caterina Fratto, Alessia Pagana, Maria Fiore, Gaetano Valenti","doi":"10.1186/s12885-025-14868-5","DOIUrl":"10.1186/s12885-025-14868-5","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the effectiveness of endocervical curettage (ECC) in detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in HPV-positive postmenopausal women with a type 3 transformation zone (TZ3) and to identify additional predictive factors.</p><p><strong>Methods: </strong>A retrospective observational study was conducted including 137 HPV-positive postmenopausal women who underwent colposcopy, ECC, and subsequent LEEP. Variables analyzed included age group, HPV genotype (16/18 vs. non-16/18), transformation zone type, cytology results, and ECC findings. Univariate and multivariable logistic regression analyses were performed to identify predictors of CIN2 + confirmed by LEEP histology.</p><p><strong>Results: </strong>CIN2 + prevalence was 27.7% (38/137); ≥CIN3 occurred in 26/137 (19.0%). In multivariable analysis, high-grade cytology (adjusted OR [aOR] 4.65; 95% CI 1.92-11.30; p < 0.001), TZ3 (aOR 3.05; 1.05-8.85; p = 0.040) and hrHPV non-16/18 (aOR 2.52; 1.08-5.90; p = 0.032) were independently associated with CIN2+, while age ≥ 51 years was not (aOR 1.28; 0.57-2.85; p = 0.55). Absolute risks of CIN2 + were 36.8% with non-16/18 vs. 16.4% with HPV16/18. ECC (cut-off CIN2+) yielded sensitivity 73.7%, specificity 77.8%, PPV 56.0% and NPV 88.5%.</p><p><strong>Conclusion: </strong>In postmenopausal women with persistent hrHPV, high-grade cytology and TZ3 are the main drivers of CIN2+ risk. ECC is most useful as a rule-out test (high NPV), whereas expedited diagnostic-therapeutic LEEP may be considered when ASC-H/HSIL coexists with TZ3 in women without fertility desire. The association between non-16/18 genotypes and CIN2+ observed here warrants confirmation in larger multicentre cohorts.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1486"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High frame rate contrast-enhanced ultrasound in hepatocellular carcinoma: biological characteristics and patient outcomes.","authors":"Lianhua Zhu, Nan Li, Shuyuan Liang, Bo Jiang, Miao Li, Yukun Luo, Xiang Fei","doi":"10.1186/s12885-025-14907-1","DOIUrl":"10.1186/s12885-025-14907-1","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1488"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data.","authors":"Della Varghese, Jenna Collins, Beth Nordstrom, Miguel Miranda, Brian Murphy, David Harland","doi":"10.1186/s12885-025-14786-6","DOIUrl":"10.1186/s12885-025-14786-6","url":null,"abstract":"<p><strong>Background: </strong>There are limited real-world data on the prevalence of brain metastases (BM) in metastatic breast cancer (mBC) across the treatment pathway, especially when stratified by human epidermal growth factor receptor 2-positive (HER2+) or HER2-negative (HER2-) status. The goals of this study were to estimate the prevalence of BM at metastatic diagnosis and at the start of each line of systemic therapy (LOT), and to describe treatment patterns and overall survival (OS) in patients with and without BM.</p><p><strong>Methods: </strong>This retrospective cohort study included adult patients in the US with mBC diagnosed between January 2013 - May 2020, with known HER2 status from an electronic health record-derived, deidentified database. Patients were followed from mBC diagnosis to last activity date or death. Descriptive statistics were used for BM prevalence, patient characteristics, and treatment patterns. OS was estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Of 12,644 patients with mBC in the database, 1923 (HER2+) and 9693 (HER2-) were included. The prevalence of BM at mBC diagnosis was 12.5% (HER2+) and 1.7% (HER2-). An NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) recommended systemic treatment for BM was received by 25.0% of patients with BM (HER2+) versus 12.8% (HER2-) during first-line treatment. The prevalence of BM (documented before or within the same month of LOT start) was 11.2%, 22.8%, and 33.0% in those with HER2+ diseases who had at least one, two, and three prior LOTs, respectively. The prevalence of BM among patients with HER2- disease was 1.6%, 2.0%, and 2.8% in those who had at least one, two, and three prior LOTs, respectively. Median OS from mBC diagnosis among patients with versus without BM was 24 versus 37 months (HER2+) and 12 versus 27 months (HER2-).</p><p><strong>Conclusions: </strong>In this real-world study of patients receiving care in US oncology clinics, the prevalence of BM in patients with mBC increased by LOT, and most were not receiving NCCN Guideline^®-recommended systemic therapies. OS was poorer in patients with BM versus without BM, especially in the HER2- population. These results highlight a need for more effective treatments for patients with mBC and BM.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1475"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-specific uptake of ⁶⁸Ga-FAPI PET/CT in the pancreas and its related factor: a retrospective, single-center study.","authors":"Liu Xiao, Liu Yang, Lin Li, Wenjie Zhang","doi":"10.1186/s12885-025-14736-2","DOIUrl":"10.1186/s12885-025-14736-2","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to analyze the characteristics of non-specific uptake(NSU) of ⁶⁸Ga-FAPI in the pancreas and explore potential independent factors associated with its presence on ⁶⁸Ga-FAPI PET/CT images.</p><p><strong>Materials: </strong>This retrospective study included 122 patients who underwent ⁶⁸Ga-FAPI PET/CT examinations for stage and re-stage of abdominal malignant tumor, dividing patients with pancreatic NSU and patients without pancreatic NSU. Patients with clinical evidence of pancreatitis or pancreas tumor were excluded. Univariate and multivariate regression analysis were used to identify factors associated with pancreatic NSU. ROC curve analysis was used to evaluate optimal cut-off for the presence of pancreatic NSU.</p><p><strong>Results: </strong>A total of 122 patients were included in the final analysis, comprising 42 patients with pancreatic NSU and 80 patients without NSU. The SUVmax was 7.94 ± 5.39 and 2.01 ± 0.50 in NSU and non-NSU group respectively on ⁶⁸Ga-FAPI PET/CT. Univariate and multivariate regression analysis identified independent risk factors associated with pancreatic NSU, including diabetes (OR: 6.894, 95% CI: 1.208-39.331, P = 0.03), hematocrit (OR: 0.858, 95% CI: 0.749-0.983, P = 0.027), and CRP (OR: 1.029, 95% CI: 1.009-1.049, P = 0.005). ROC curve analysis determined the optimal cut-off of 17.85 and 37.5 for CRP and hematocrit in predicting NSU in the pancreas on ⁶⁸Ga-FAPI PET/CT imaging.</p><p><strong>Conclusion: </strong>Pancreatic diffuse NSU is associated with the presence of diabetes, lower hematocrit levels, and higher CRP levels. These findings may assist clinicians and nuclear medicine physicians in interpreting imaging appearances, helping to avoid misdiagnosis.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1479"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials.","authors":"Suguru Kojima, Naoki Inui, Takahito Suzuki, Kazuki Tanaka, Masato Karayama, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Koji Nishimoto, Shun Matsuura, Dai Hashimoto, Takashi Matsui, Kazuhiro Asada, Takafumi Suda","doi":"10.1186/s12885-025-14985-1","DOIUrl":"10.1186/s12885-025-14985-1","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced nausea and vomiting is a common adverse event of cancer treatments. Despite prophylactic antiemetic treatment, nausea remains a particular problem. We aimed to identify risk factors and clarify the usefulness of olanzapine for the control of carboplatin-induced nausea.</p><p><strong>Methods: </strong>This was a pooled analysis of data from a single-arm, open-label, phase II trial and a prospective, randomized, double-blind, placebo-controlled phase III trial. We combined data from two trials with similar inclusion and exclusion criteria and treatment schedules. Chemotherapy-naïve patients aged ≥ 20 years with solid cancers who were scheduled to receive a first course of carboplatin-containing chemotherapy were enrolled. Patients in the olanzapine and placebo groups received olanzapine 5 mg or placebo, respectively, in combination with the neurokinin-1 (NK₁) receptor antagonist aprepitant, a 5-hydroxytryptamine-3 (5-HT₃) receptor antagonist, and dexamethasone. Olanzapine was administered on days 1-4 after the evening meal. The primary endpoint was the proportion of patients without nausea in the overall phase (0-120 h). Intergroup differences and their 95% confidence intervals (CIs) were estimated in each phase and population. Univariable and multivariable logistic regression analyses were performed to determine the risk factors associated with nausea, appetite loss, and complete response (no vomiting and no rescue medication use) rate. Odds ratios (ORs), 95% CIs, and p-values for each background factor were calculated.</p><p><strong>Results: </strong>A total of 388 patients were evaluated (79.4% male, median age 72 years), including 208 patients in the olanzapine group. Overall, 87.5% in the olanzapine group and 75.0% in the placebo group were free of nausea (intergroup difference 12.5%, 95% CI, 4.7-20.3, p = 0.002), and the difference in proportion of patients reporting no appetite loss was 20.6% (95% CI, 11.5-29.6, p < 0.001). The overall complete response rates were 88.0% in the olanzapine group and 80.6% in the placebo group (p = 0.049). Multivariable analysis only identified no olanzapine use as significantly associated with a decreased risk of nausea (adjusted OR, 0.45, 95% CI, 0.26-0.76).</p><p><strong>Conclusions: </strong>This analysis revealed that adding olanzapine to triple antiemetic therapy was associated with improved control of carboplatin-induced nausea.</p><p><strong>Trial registration: </strong>The trial was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN) 000026739, registered on 1 April 2017 and 000037749, registered on 1 September 2019.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1494"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prognostic risk model for colorectal cancer based on microsatellite stability-associated genes.","authors":"Xuefeng Zheng, Yunduan He, Zhan Tuo, Kuikui Zhu, Hong Ge, Xu Wang","doi":"10.1186/s12885-025-14918-y","DOIUrl":"10.1186/s12885-025-14918-y","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) patients have a high recurrence rate, impacting survival. Microsatellite instability (MSI) is strongly linked to CRC development, making the MSI-related prognostic genes crucial for diagnosis and treatment.</p><p><strong>Methods: </strong>This study used CRC datasets, including TCGA-CRC, GSE17537, GSE39582, and GSE18088. We analyzed differential expression between CRC and control samples, and between MSS and MSI-H samples. Key genes were identified through a co-expression network and used to develop a prognostic risk model. The model's performance was validated in GSE17537, and independent prognostic factors were identified to construct a survival nomogram. We also explored pathways linked to the risk groups and their association with the tumor immune microenvironment, and predicted potential therapeutic agents for CRC.</p><p><strong>Results: </strong>We identified 11 prognostic genes (CHGB, FABP4, PLIN4, PLIN1, RPRM, C7, AQP8, C2CD4A, APLP1, ADH1B, and CD36) and developed a CRC risk model that showed significant survival differences in the TCGA-CRC cohort and GSE17537, with AUCs over 0.6 at 3, 5, and 7 years. Independent prognostic factors included risk score, age, tumor stage, and pathological N, and a nomogram was created for survival prediction. The identified genes may influence CRC through various pathways and are linked to immune responses. Bleomycin emerged as a potential treatment, with CHGB and RPRM regulated by non-coding RNAs and transcription factors, possibly affecting CRC development.</p><p><strong>Conclusions: </strong>Our analysis of microsatellite stability-associated genes in CRC highlights their impact on TIME, clinicopathological features, and prognosis, providing new insights into predicting prognosis and developing personalized treatments.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1490"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multilevel factors associated with clinical breast examination uptake among women in the Northern Region of Ghana: a cross-sectional survey.","authors":"Agani Afaya, Hyeonkyeong Lee, So Yoon Kim, Chang Gi Park, Min Kyeong Jang, Sue Kim","doi":"10.1186/s12885-025-14550-w","DOIUrl":"10.1186/s12885-025-14550-w","url":null,"abstract":"<p><strong>Background: </strong>Despite the World Health Organization's recommendation of clinical breast examination (CBE) in resource-limited settings where mammography services are unavailable, the participation rate among women in Ghana remains low. This study examined multilevel factors associated with CBE uptake among women in the Northern Region of Ghana.</p><p><strong>Methods: </strong>A multi-stage cluster sampling technique was employed to recruit women aged 25 years and older from 30 communities in the Tamale metropolis, Northern Region of Ghana. To determine the factors associated with CBE uptake, multilevel logistic regression models were fitted. The outcome of the fixed effects analysis was presented using adjusted odds ratios (aOR), with a 95% confidence interval (CI) and a p-value of less than 0.05.</p><p><strong>Results: </strong>Approximately 1,543 women were recruited from 30 communities with 48 clusters. The prevalence of CBE uptake was 23%. From the fixed effects results, women with tertiary education (aOR = 2.53, 95%CI = 1.49-4.29) were more likely to have CBE compared to those with no formal education. Women with increased knowledge of breast cancer (BC) were more likely to undergo CBE (aOR = 1.04, 95%CI = 1.00-1.07). The higher the perceived susceptibility to BC, the higher the likelihood of undergoing CBE (aOR = 1.25, 95%CI = 1.06-1.47). Women with increased perceived barriers to BC screening (aOR = 0.54, 95%CI = 0.41-0.73) and higher perceived fear of BC (aOR = 0.72, 95%CI = 0.57-0.91) were less likely to undergo CBE. Women who received recommendations from friends (aOR = 1.99, 95%CI = 1.25-3.18) and healthcare providers (aOR = 1.55, 95%CI = 1.00-2.39) were more likely to utilize CBE compared to their counterparts. Women in communities with health facilities (aOR = 2.14, 95%CI = 1.43-3.21) and those who resided in urban areas (aOR = 1.72, 95%CI = 1.10-2.69) were more likely to utilize CBE than their counterparts.</p><p><strong>Conclusion: </strong>The findings signify that a multifactorial systematic approach is required to increase CBE uptake among Ghanaian women. We recommend a comprehensive community-based education program about BC, targeted at raising awareness of breast health and improving the knowledge of the disease, together with the benefits of CBE uptake. Concurrently, improving access to health facilities and CBE services is needed.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1476"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined technology-enhanced home exercise and acupressure (TEHEplus) program on symptoms among cancer patients receiving immunotherapy: a feasibility study.","authors":"Nada Lukkahatai, Chitchanok Benjasirisan, Aomei Shen, Junxin Li, Sarah Allgood, Frank Thomas, Artyom Karyukin, Jennifer Y Sheng, Jessica Engle, Ta-Ya Lee, Leorey N Saligan","doi":"10.1186/s12885-025-14887-2","DOIUrl":"10.1186/s12885-025-14887-2","url":null,"abstract":"<p><strong>Background: </strong>Cancer patients receiving immunotherapy often experience symptoms impacting their well-being. The present study aimed to develop and test the feasibility of a 12-week Technology-Enhanced Home Exercise and acupressure (TEHEplus) program to improve symptoms (fatigue, pain, sleep, anxiety, depression), social functioning, physical performance, and serum biomarkers (brain-derived neurotrophic factor, heat shock protein 90 levels.) METHODS: A two-phase design was employed. Phase 1 involved program development; Phase 2 was a pilot feasibility study. Participants with solid tumor cancers were recruited from cancer centers in Maryland and randomly assigned to four groups: Usual Care Control (UC), Technology-Enhanced Home Exercise (TEHE) alone, Acupressure alone (ACU), and TEHEplus. Feasibility was measured by enrollment duration, intervention adherence, and daily survey response rates. Outcomes were measured at baseline and program completion.</p><p><strong>Results: </strong>In phase 1, four participants (age 56-82) provided feedback on online training, smartphone application, intervention duration, and outcome measures. In Phase 2, 40 participants (10 per group) were recruited over 12 months, with 43% (n = 17) completing all daily surveys. TEHEplus participants achieved 50% of exercise goals, and 78% adhered to the acupoint recommendations. TEHEplus participants showed significant improvements in fatigue (p = 0.02), pain inference (p = 0.30), and social functioning (p = 0.03); TEHE participants improved only in social functioning (p = 0.03).</p><p><strong>Conclusion: </strong>TEHEplus is feasible and shows promise for symptom alleviation. Preliminary findings suggest potential benefits in symptom management and functional outcomes. However, further studies with larger and more diverse samples are warranted to explore its efficacy and generalizability.Further studies with larger, more diverse populations are needed to confirm its efficacy. TEHEplus may enhance symptom management and improve functional outcomes for cancer survivors undergoing immunotherapy.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov ID NCT03576274 Trial Registration Date: 06/07/2018.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1481"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hearing, smell, and cognitive function after cancer treatment.","authors":"Stavros Potsakis, Juha Tapio Silvola, Ellen Karine Grov","doi":"10.1186/s12885-025-14861-y","DOIUrl":"10.1186/s12885-025-14861-y","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the sensory and cognitive impact of cancer and its treatment, focusing on possible chemotherapy-induced hearing and olfactory impairment, and cognitive function. The primary aim is to evaluate the effectiveness and feasibility of an extended test battery for assessing sensory and cognitive function in cancer patients, providing foundational knowledge for a larger study. A secondary aim is to examine associations between chemotherapy types and sense-neurodegenerative function.</p><p><strong>Design: </strong>An observational cross-sectional, pilot study evaluated hearing, olfactory function, and cognitive function in first-line chemotherapy patients without prior brain injuries and ototoxic or otological histories. Self-reported outcomes on communication strategies, tinnitus and olfaction were collected. Data analysis applied descriptive statistics with t-tests, and Fisher´s exact tests to compare auditory, olfactory, and cognitive performance between treatment groups.</p><p><strong>Study sample: </strong>Thirteen cancer survivors (n = 13), six (n = 6) females and seven (n = 7) males who received two different types of chemotherapy.</p><p><strong>Results: </strong>No significant differences were observed between the chemotherapy groups in audiological and olfactory tests, cognitive assessment, or self-reported outcomes. However, among those receiving platinum-based chemotherapy, participants reported greater use of communication strategies in specific areas.</p><p><strong>Conclusion: </strong>No significant differences in hearing, olfactory, cognitive, and self-reported outcomes were found when examining cancer patients receiving two different chemotherapy types. The study highlights the need for advanced diagnostic tools to detect hearing, olfactory, and cognitive function in cancer survivors.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1485"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}